Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...